drugset / Trial / NCT00209027

The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia

NCT00209027

Non-randomizedParallel-groupOpen-label

Summary

The objective of this study is to determine whether subjects with negative symptoms of schizophrenia have abnormal functioning of brain circuits relevant to reward processing, and to determine whether any such abnormalities are normalized by treatment with aripiprazole.

Timeline

Start
2005-04
Primary completion
2010-12
Completion
2011-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 30 mg Oral

Indications